Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report
Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists...
Main Authors: | Vittorio Gebbia, Dario Piazza, Maria Rosaria Valerio |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-09-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/518779 |
Similar Items
-
Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01) -
Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study
by: Melissa Mahoney, et al.
Published: (2020-12-01) -
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
by: Patrick Neven, et al.
Published: (2021-08-01) -
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
by: Muh-Lii Liang, et al.
Published: (2020-12-01) -
Profile of abemaciclib and its potential in the treatment of breast cancer
by: Martin JM, et al.
Published: (2018-08-01)